NCT00003853已完成2 期
Phase II Trial of 4'-IODO-4'-Deoxydoxorubicin in Primary Amyloidosis (AL)
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 45
- 试验地点
- 6
研究概览
简要总结
RATIONALE: 4'-Iodo-4'-deoxydoxorubicin may improve organ dysfunction and ease symptoms caused by primary systemic amyloidosis.
PURPOSE: Phase II trial to study the effectiveness of 4'-iodo-4'-deoxydoxorubicin in treating patients who have primary systemic amyloidosis.
详细描述
OBJECTIVES: I. Evaluate the clinical efficacy of 4'-iodo-4'-deoxydoxorubicin in producing palliation of symptoms and/or improvement of organ dysfunction caused by organ infiltration by amyloid in patients with primary systemic amyloidosis. II. Assess the safety profile, with emphasis on cardiac safety, of this drug in these patients. III. Evaluate the time to progression of amyloidosis-associated clinical symptoms and/or organ dysfunction, duration of response, and survival of these patients on this regimen.
OUTLINE: Patients receive 4'-iodo-4'-deoxydoxorubicin IV over 1 hour once a week for 4 weeks. Courses are repeated every 12 weeks. Treatment continues for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients are followed every 6 months.
PROJECTED ACCRUAL: A total of 45 patients will be accrued for this study within 1 year.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •DISEASE CHARACTERISTICS: Histochemically proven primary systemic amyloidosis (AL) No presence of non-AL amyloidosis No amyloid-specific syndrome (e.g., skin purpura or carpal tunnel syndrome) as only evidence of disease No vascular amyloid only in a bone marrow biopsy specimen or in a plasmacytoma Must have symptomatic organ involvement with amyloid (e.g., liver, mild cardiac, renal, or soft tissue involvement, or grade 1 or 2 peripheral neuropathy) Demonstrable M-protein in the serum/urine OR Clonal population of plasma cells in the bone marrow OR Immunohistochemical stain with anti-light chain antisera of amyloid fibrils No clinically overt multiple myeloma (i.e., monoclonal BMPC greater than 20% and at least one of the following: bone lesions, anemia, or hypercalcemia)
- •PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-3 Life expectancy: Not specified Hematopoietic: Absolute neutrophil count at least 1,500/mm3 Platelet count at least 100,000/mm3 Hepatic: Total bilirubin less than 2.0 mg/dL OR Direct bilirubin no greater than 1.0 mg/dL Alkaline phosphatase no greater than 4 times upper limit of normal (ULN) ALT or AST no greater than 3 times ULN Renal: Creatinine clearance greater than 40 mL/min Cardiovascular: Echocardiographic ejection fraction greater than 50% At least 3 years since prior enzyme documented myocardial infarction Interventricular septal thickness no greater than 20 mm No New York Heart Association class III or IV heart failure No grade 2 or 3 A-V block No chronic atrial fibrillation No sustained (greater than 30 seconds) ventricular tachycardia or frequent episodes (greater than 20 in 24 hours) of nonsustained ventricular tachycardia or ventricular pairs, detected by 24-hour ambulatory electrocardiographic monitoring Other: Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception HIV positive allowed No uncontrolled infection No severe diarrhea not controllable with medication or that requires total parenteral nutrition No other concurrent active malignancy except nonmelanoma skin cancer or cervical cancer
- •PRIOR CONCURRENT THERAPY: Biologic therapy: At least 6 weeks since prior interferon alfa Chemotherapy: No prior anthracyclines greater than 120 mg/m2 At least 6 weeks since prior melphalan or other alkylating agents Endocrine therapy: At least 6 weeks since prior high dose dexamethasone Radiotherapy: Not specified Surgery: Not specified
排除标准
- 未提供
研究者
研究点 (6)
Loading locations...
相似试验
终止
1 期
Iododoxorubicin in Treating Patients With Primary Systemic AmyloidosisPrimary Systemic AmyloidosisNCT00030381National Cancer Institute (NCI)22
进行中（未招募）
1 期
Ropidoxuridine in Treating Patients With Advanced Gastrointestinal Cancer Undergoing Radiation TherapyAdvanced Bile Duct CarcinomaStage II Esophageal Cancer AJCC v7Stage II Pancreatic Cancer AJCC v6 and v7Stage IIA Esophageal Cancer AJCC v7Stage IIA Pancreatic Cancer AJCC v6 and v7Stage IIB Esophageal Cancer AJCC v7Stage IIB Pancreatic Cancer AJCC v6 and v7Stage III Colon Cancer AJCC v7Stage III Esophageal Cancer AJCC v7Stage III Gastric Cancer AJCC v7Stage III Liver CancerStage III Pancreatic Cancer AJCC v6 and v7Stage III Rectal Cancer AJCC v7Stage III Small Intestinal Cancer AJCC v7Stage IIIA Colon Cancer AJCC v7Stage IIIA Esophageal Cancer AJCC v7Stage IIIA Gastric Cancer AJCC v7Stage IIIA Rectal Cancer AJCC v7Stage IIIA Small Intestinal Cancer AJCC v7Stage IIIB Colon Cancer AJCC v7Stage IIIB Esophageal Cancer AJCC v7Stage IIIB Gastric Cancer AJCC v7Stage IIIB Rectal Cancer AJCC v7Stage IIIB Small Intestinal Cancer AJCC v7Stage IIIC Colon Cancer AJCC v7Stage IIIC Esophageal Cancer AJCC v7Stage IIIC Gastric Cancer AJCC v7Stage IIIC Rectal Cancer AJCC v7Stage IV Colon Cancer AJCC v7Stage IV Esophageal Cancer AJCC v7Stage IV Gastric Cancer AJCC v7Stage IV Liver CancerStage IV Pancreatic Cancer AJCC v6 and v7Stage IV Rectal Cancer AJCC v7Stage IV Small Intestinal Cancer AJCC v7Stage IVA Colon Cancer AJCC v7Stage IVA Liver CancerStage IVA Rectal Cancer AJCC v7Stage IVB Colon Cancer AJCC v7Stage IVB Liver CancerStage IVB Rectal Cancer AJCC v7NCT02381561National Cancer Institute (NCI)19
进行中（未招募）
2 期
Pediatric Trial of Indoximod With Chemotherapy and Radiation for Relapsed Brain Tumors or Newly Diagnosed DIPGMedulloblastomaDiffuse Intrinsic Pontine GliomaEpendymomaGlioblastomaNCT04049669Theodore S. Johnson130
已完成
2 期
Treatment With Pazopanib for Neoadjuvant Breast CancerNeoplasms, BreastNCT00849472GlaxoSmithKline101
进行中（未招募）
1 期
Ropidoxuridine and Whole Brain Radiation Therapy in Treating Patients With Brain MetastasesHematopoietic and Lymphoid Cell NeoplasmMalignant Solid NeoplasmMetastatic Malignant Neoplasm in the BrainNCT02993146National Cancer Institute (NCI)11